TY - JOUR
T1 - Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver
AU - Domènech, Marta
AU - Muñoz Marmol, Ana M.
AU - Mate, Jose Luis
AU - Estival, Anna
AU - Moran, Teresa
AU - Cucurull, Marc
AU - Saigi, Maria
AU - Hernandez, Ainhoa
AU - Sanz, Carolina
AU - Hernandez-Gallego, Alba
AU - Urbizu, Aintzane
AU - Martinez-Cardus, Anna
AU - Bernat, Adrià
AU - Carcereny, Enric
N1 - Publisher Copyright:
Copyright: © 2021 Domènech et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2021/8/31
Y1 - 2021/8/31
N2 - Non-small cell lung cancers (NSCLC) are the most common type of lung cancer and can be classified according to the presence of mutually exclusive oncogenic drivers. The majority of NSCLC patients present a non-actionable oncogenic driver, and treatment resistance through the amplification of the MET proto-oncogene (MET) or the expression of programmed cell death protein 1 ligand (PD-L1) is common. Herein, we investigated the relation between MET gene amplification and PD-L1 expression in patients with advanced NSCLC and no other actionable oncogenic driver (i.e., EGFR, ALK, ROS1). Our retrospective observational study analyzed data from 48 patients (78% men, median age 66 years) admitted to the Germans Trias i Pujol Hospital, Spain, between July 2015 and February 2019. Patients presenting MET amplification showed a higher proportion of PD-L1 expression (93% vs. 39%; p < 0.001) and overexpression (64% vs. 27%; p = 0.020) than those with non-amplified MET. PD-L1 expression was not significantly different when analyzed by sex (p = 0.624), smoking history (p = 0.429), and Eastern Cooperative Oncology Group Performance Status (p = 0.597) Overall survival rates were not significantly affected by MET amplification (high and intermediate amplification vs low amplification and non-amplificated) (p = 0.252) nor PD-L1 expression (> vs =< 50%) (p = 0.893). In conclusion, a positive correlation was found between MET gene amplification and PD-L1 expression and highly expressed (above 50%) in patients with NSCLC and no other actionable oncogenic driver. It could be translated as new guided-treatment oportunities for these patients.
AB - Non-small cell lung cancers (NSCLC) are the most common type of lung cancer and can be classified according to the presence of mutually exclusive oncogenic drivers. The majority of NSCLC patients present a non-actionable oncogenic driver, and treatment resistance through the amplification of the MET proto-oncogene (MET) or the expression of programmed cell death protein 1 ligand (PD-L1) is common. Herein, we investigated the relation between MET gene amplification and PD-L1 expression in patients with advanced NSCLC and no other actionable oncogenic driver (i.e., EGFR, ALK, ROS1). Our retrospective observational study analyzed data from 48 patients (78% men, median age 66 years) admitted to the Germans Trias i Pujol Hospital, Spain, between July 2015 and February 2019. Patients presenting MET amplification showed a higher proportion of PD-L1 expression (93% vs. 39%; p < 0.001) and overexpression (64% vs. 27%; p = 0.020) than those with non-amplified MET. PD-L1 expression was not significantly different when analyzed by sex (p = 0.624), smoking history (p = 0.429), and Eastern Cooperative Oncology Group Performance Status (p = 0.597) Overall survival rates were not significantly affected by MET amplification (high and intermediate amplification vs low amplification and non-amplificated) (p = 0.252) nor PD-L1 expression (> vs =< 50%) (p = 0.893). In conclusion, a positive correlation was found between MET gene amplification and PD-L1 expression and highly expressed (above 50%) in patients with NSCLC and no other actionable oncogenic driver. It could be translated as new guided-treatment oportunities for these patients.
KW - MET amplification
KW - Non-small cell lung cancer
KW - Oncogenic driver
KW - PD-L1
KW - Smoking habit
KW - MET amplification
KW - Non-small cell lung cancer
KW - Oncogenic driver
KW - PD-L1
KW - MET amplification
KW - Non-small cell lung cancer
KW - Oncogenic driver
KW - PD-L1
UR - http://www.scopus.com/inward/record.url?scp=85114435426&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.28045
DO - 10.18632/oncotarget.28045
M3 - Article
C2 - 34504652
AN - SCOPUS:85114435426
SN - 1949-2553
VL - 12
SP - 1802
EP - 1810
JO - Oncotarget
JF - Oncotarget
IS - 18
ER -